Shan et al., 2023 - Google Patents
Activated wake systems in narcolepsy Type 1Shan et al., 2023
View PDF- Document ID
- 9096307689376396088
- Author
- Shan L
- Linssen S
- Harteman Z
- den Dekker F
- Shuker L
- Balesar R
- Breesuwsma N
- Anink J
- Zhou J
- Lammers G
- Swaab D
- Fronczek R
- Publication year
- Publication venue
- Annals of Neurology
External Links
Snippet
Objective Narcolepsy type 1 (NT1) is assumed to be caused solely by a lack of hypocretin (orexin) neurotransmission. Recently, however, we found an 88% reduction in corticotropin‐ releasing hormone (CRH)‐positive neurons in the paraventricular nucleus (PVN). We …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miller et al. | Therapeutic approaches to enhance PINK1/Parkin mediated mitophagy for the treatment of Parkinson’s disease | |
| Wray et al. | NMDAR-independent, cAMP-dependent antidepressant actions of ketamine | |
| Han et al. | Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features | |
| Comai et al. | The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology | |
| Cunningham et al. | Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease | |
| Salehi et al. | Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome | |
| Caberlotto et al. | Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain | |
| Mogi et al. | Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2 | |
| Bouckaert et al. | ECT: its brain enabling effects: a review of electroconvulsive therapy–induced structural brain plasticity | |
| Hall et al. | Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease | |
| Corcoran et al. | Disruption of the retinoid signalling pathway causes a deposition of amyloid β in the adult rat brain | |
| Zhang et al. | Corticotropin‐releasing factor receptor‐1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease | |
| Müller et al. | Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids | |
| Delay et al. | Increased LINGO1 in the cerebellum of essential tremor patients | |
| Medina-Rodríguez et al. | Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis | |
| Wood et al. | Cellular adaptations of dorsal raphe serotonin neurons associated with the development of active coping in response to social stress | |
| Di Pardo et al. | Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood–brain barrier integrity and exerts therapeutic effect in an animal model of Huntington’s disease | |
| Shan et al. | Activated wake systems in narcolepsy Type 1 | |
| Adeosun et al. | Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease | |
| Ramírez-Jarquín et al. | Deletion of SUMO1 attenuates behavioral and anatomical deficits by regulating autophagic activities in Huntington disease | |
| Xia et al. | The involvement of transient receptor potential canonical type 1 in skeletal muscle regrowth after unloading‐induced atrophy | |
| Shan et al. | Reduced numbers of corticotropin‐releasing hormone neurons in narcolepsy type 1 | |
| Liao et al. | The disturbance of hippocampal C a MKII/PKA/PKC phosphorylation in early experimental diabetes mellitus | |
| Paldino et al. | Modulation of Phospho‐CREB by Systemically Administered Recombinant BDNF in the Hippocampus of the R6/2 Mouse Model of Huntington’s Disease | |
| Akwa et al. | Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies |